Precipio Inc
PRPO
View Detailed Chart
24.880USD
-1.660-6.25%
Market hours （ET）Quotes delayed by 15 min
16.51KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.25%
5 Days
-10.76%
1 Month
+3.32%
6 Months
+35.19%
Year to Date
+8.27%
1 Year
+296.81%
View Detailed Chart
TradingKey Stock Score of Precipio Inc
Currency: USD Updated: 2026-03-27Key Insights
Precipio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precipio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precipio Inc Highlights
StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.53M.
Undervalued
The company’s latest PE is -32.24, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 342.90K shares, increasing 20.32% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.50K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.14.
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Precipio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Precipio Inc Info
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEODanieli (Ilan S)
Websitehttps://www.precipiodx.com/
Related Instruments
+0.88%
-2.30%
-1.30%
-3.59%
-1.79%
-2.56%
-0.33%
-2.84%
-1.23%
-2.00%
-9.54%
-2.18%
-4.62%
-2.28%
+2.88%
+0.13%
-1.14%
-1.06%
-1.05%
-0.49%Popular Symbols
246.370
-2.430 (-0.98%)
165.490
-2.030 (-1.21%)
66581.710
-2.340 (-0.00%)
252.335
-21.015 (-7.69%)
2027.140
+27.140 (+1.36%)
355.555
-6.275 (-1.73%)
4499.580
+7.060 (+0.16%)
102.482
+1.873 (+1.86%)
1.146
-0.005 (-0.40%)
159.626
-0.626 (-0.39%)
